Skip to content
Buy This GLP
← Research
Evidence

Food noise fell by half, measured against a remembered baseline

A 550-person survey scored food preoccupation at 6 out of 20 on treatment against 13 before. Nobody was asked before they started.

Carla Medina6 min read
Food Noise Questionnaire, out of 2013before(recalled)6after(reported)Dashed outline marks the bar nobody measured at the time.

“Food noise” is the phrase people actually use for the constant background negotiation with what is in the fridge, and it is almost absent from clinical instruments. A survey of 550 US adults taking injectable semaglutide tried to put a number on it, using a five-item questionnaire scored out of 20 [1]. It is the quantitative companion to the interview work covered in what patients said when asked.

The reported change is large. Median score after treatment was 6, with an interquartile range of 3 to 10, against a median of 13 recalled for the period before starting. Agreement with individual statements indicating food noise dropped from between 47% and 63% to between 15% and 20%, and the pattern held across subgroups defined by how long people had been treated and by baseline BMI.

The sample compounds the problem rather than offsetting it. Respondents came from a commercial opinion panel and were 86% women, 79% white, with a mean age of 53, and 81% had been taking semaglutide for at least four months — meaning people who stopped early are largely absent. A survey of continuing users cannot describe the experience of the people who quit, who are the majority within a year according to two thirds stop within a year.

None of that makes the phenomenon fictional, and it would be a mistake to dismiss it on methodological grounds alone. Reduced preoccupation with food is the effect people describe most consistently and most spontaneously, it appears in qualitative interviews where nobody prompted for it, and a plausible mechanism exists in the reward circuitry these drugs act on. What this survey cannot do is tell you the size of the change, because the number it is measured against was never recorded.

For someone weighing a purchase, the useful reading is qualitative even though the study is quantitative: this is a commonly reported benefit, it is not what the drug is sold or priced on, and the figure attached to it here should not be treated as the amount of relief to expect. The gap between what is advertised and what is delivered is a running theme in the headline against the bill and the super-responder brand comparison.

Frequently asked

Do these drugs reduce food noise?
It is the benefit users report most consistently, and it appears in interviews where nobody prompted for it. This survey supports that it happens without establishing how large the change is.
Why does the baseline matter so much?
Because it was never measured. Participants already taking the drug, most of them satisfied with it, were asked to recall their pre-treatment state, and people who believe a treatment worked systematically remember a worse starting point.
Who was surveyed?
550 adults from a commercial opinion panel, 86% women and 79% white, with 81% having taken semaglutide for at least four months — so people who stopped early are largely missing.

Sources

  1. [1] Arnaut T, Duncan S, Faurby M, Hahn-Pedersen JH, Kvist K, Steenackers N, Buse JB (2026). Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey Advances in Therapy. PMID 42217114

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk

More in Evidence